BioCardia, Inc. BCDA
Set alert
0.86 USD -0.07 -7.02%
At close · Oct 30
0.86 0.00 0.00%
After hours · Oct 30, 5:45 PM ET
0.861 Day range 0.92
0.77 52-week range 1.47
- YTD
- -31.12%
- 1 year
- -31.67%
- Open
- 0.92
- Prev close
- 0.926
- Mkt cap
- 13.03M
- Vol
- 79.32K
- Avg vol
- 243.28K
- EPS
- -0.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.861
- High
- 0.92
- Forward P/E
- -1.57
- Beta
- 1.27
- Short ratio
- 1.41
- Inst. own
- 2.21%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.28
- 200-d avg
- 3.62
- 1y target
- 25.00
6M chart
Signals (22)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 9, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 7, 2026 | 3 months ago |
| RSI: Overbought | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 16, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 4 months ago |
| RSI: Oversold | May 21, 2026 | 5 months ago |
| RSI: Oversold | May 18, 2026 | 5 months ago |
Key statistics
- Market cap
- 9.17M
- Enterprise value
- 4.00M
- Trailing P/E
- 0.00
- Forward P/E
- -1.57
- PEG ratio
- 0.00
- Price / sales
- 21.42
- Price / book
- 0.00
- EPS (TTM)
- -4.03
- Beta
- 1.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 428.00K
- Revenue growth
- -93.00%
- Free cash flow
- -3.85M
- Total cash
- 1.42M
- Total debt
- 1.14M
- Return on equity
- 0.00%
- Shares outstanding
- 4.58M
- Short % of float
- 2.65%
- 50-day average
- 2.28
- 200-day average
- 3.62
Analyst view
Consensus: none
Price target (mean) 25.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.87.
Financials — quick view
BCDA Revenue — quarterly 0
BCDA Net income — quarterly -1.61M
BCDA EPS — quarterly -0.13
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -1.19 | -0.61 | +0.58 | +48.74% |
| Aug 13, 2024 | Jun 1, 2024 | -0.10 | -0.88 | -0.78 | -780.00% |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -1.35 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | -1.65 | -1.35 | +0.30 | +18.18% |
| Nov 8, 2023 | Sep 1, 2023 | -1.80 | -1.80 | 0.00 | 0.00% |
| Aug 9, 2023 | Jun 1, 2023 | -2.25 | -2.55 | -0.30 | -13.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- biocardia.com
News
- BioCardia Receives FDA Acceptance For Its Pre-Submission Package For Marketing Clearance Of Its Helix Catheter For Therapeutic And Diagnostic Agent Delivery
- BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
- BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
- BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The Heart
- BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
- BioCardia Advancing Towards Shonin Pre-Market Regulatory Submission To Japan's Pharmaceutical And Medical Device Agency In Q4; Plans To File Follow-On De Novo Pre-Submission For Helix Transendocardial Delivery Catheter System
- BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
- BioCardia Shares Fall 10% After Hours: Here's Why
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
Your note
Sign in to keep a note on BCDA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN JIM L | Director | Stock Award(Grant) | Sep 2, 2024 | 109,673 |
| ALTMAN PETER | Chief Executive Officer | Purchase | Dec 4, 2024 | 105,581 |
| BLANK ANDREW SCOTT | Director | Stock Award(Grant) | Sep 2, 2024 | 0 |
| FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | Sale | Jan 18, 2024 | 0 |
| GILLIS EDWARD M | Officer | Stock Award(Grant) | May 17, 2023 | 40,490 |
| MCCLUNG DAVID | Chief Financial Officer | Stock Award(Grant) | Oct 10, 2024 | 30,008 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Susquehanna International Group, LLP | 1.54% | 70,596 | 141.19K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.32% | 14,736 | 29.47K | Sep 29, 2024 |
| Vanguard Group Inc | 0.28% | 12,884 | 25.77K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 1,282 | 2.56K | Sep 29, 2024 |
| Pingora Partners LLC | 0.02% | 1,036 | 2.07K | Sep 29, 2024 |
| Global Retirement Partners, LLC | 0.01% | 411 | 822 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.28% | 12,616 | 25.23K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.17% | 7,967 | 15.93K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 3,237 | 6.47K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 2,964 | 5.93K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 2,162 | 4.32K | Oct 30, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 47 | 94 | Sep 29, 2024 |